Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirum’s Board of Directors...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 9, 2024, the Compensation Committee of Mirum’s Board of Directors...
Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirum’s Board of Directors...
La Commission européenne accorde une autorisation de mise sur le marché au LIVMARLI pour le traitement de la PFIC chez les patients âgés de...
Die Europäische Kommission erteilt LIVMARLI die Marktzulassung für die Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten. Die...
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive...
Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only...
- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.